SEC Form 4 · accession 0001992260-26-000009
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simrat Randhawa
Officer — EVP, Head of R&D
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2026 | M | 7,500 | $17.88 | A | 11,500 | D | |
| Common Stock | Sep 1, 2026 | M | 6,249 | $21.77 | A | 17,749 | D | |
| Common Stock | Sep 1, 2026 | M | 9,375 | $22.07 | A | 27,124 | D | |
| Common StockF2 | Sep 1, 2026 | S | 2,600 | $105.19 | D | 24,524 | D | |
| Common StockF3 | Sep 1, 2026 | S | 7,215 | $106.25 | D | 17,309 | D | |
| Common StockF4 | Sep 1, 2026 | S | 13,309 | $106.74 | D | 4,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $17.88 | Sep 1, 2026 | M | 7,500 | D | — | Jan 23, 2034 | Common Stock | 7,500 | 56,776 | D |
| Stock Option (Right to Buy)F6 | $21.77 | Sep 1, 2026 | M | 6,249 | D | — | May 22, 2034 | Common Stock | 6,249 | 41,676 | D |
| Stock Option (Right to Buy)F7 | $22.07 | Sep 1, 2026 | M | 9,375 | D | — | Feb 3, 2035 | Common Stock | 9,375 | 87,500 | D |
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.50 to $105.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.53 to $106.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.53 to $107.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F6The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F7The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.